Olaparib

Generic Name: Olaparib

Brand Names: Lynparza

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃FN_₄O_₃

CAS Number: 763113-22-0

Unique Ingredient Identifier: WOH1JD9AR8

Background: Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...

Indication: Ovarian cancer

Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions: Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer

Associated Therapies: Maintenance therapy

Clinical Trials

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer

Phase 1

Suspended

Conditions: Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
Endometrial Serous Adenocarcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Olaparib
Biological: Trastuzumab Deruxtecan

First Posted Date: 2020-10-14

Last Posted Date: 2024-07-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT04585958

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

and more 1 locations

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Phase 2

Terminated

Conditions: Bladder Cancer
Urothelial Carcinoma

Interventions: Drug: Olaparib
Drug: Durvalumab

First Posted Date: 2020-10-08

Last Posted Date: 2021-06-16

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 140

Registration Number: NCT04579133

Locations: 🇧🇷
Centro de Pesquisa em Oncologia, Porto Alegre, Brazil

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Phase 2

Conditions: Ovarian Cancer
Ovarian and Fallopian Tube Cysts and Neoplasms
Neoplasms by Site
Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Ovarian Epithelial
Ovarian Diseases

Interventions: Drug: Anlotinib
Drug: Olaparib

First Posted Date: 2020-09-28

Last Posted Date: 2020-10-30

Lead Sponsor: Xiaoxiang Chen

Target Recruit Count: 68

Registration Number: NCT04566952

Locations: 🇨🇳
JiangSu Cancer Hospital, Nanjing, Jangsu, China

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 1

Terminated

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: PLX2853
Drug: Abiraterone acetate
Drug: Olaparib
Drug: Prednisone

First Posted Date: 2020-09-21

Last Posted Date: 2022-10-05

Lead Sponsor: Opna Bio LLC

Target Recruit Count: 19

Registration Number: NCT04556617

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇬🇧
Sarah Cannon Research Institute, London, United Kingdom
🇺🇸
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States

and more 5 locations

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Phase 2

Recruiting

Conditions: Stage IV Pancreatic Cancer AJCC v8
Metastatic Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Olaparib
Biological: Pembrolizumab

First Posted Date: 2020-09-16

Last Posted Date: 2024-12-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 88

Registration Number: NCT04548752

Locations: 🇺🇸
Sutter Davis Hospital, Davis, California, United States
🇺🇸
Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States
🇺🇸
The Carle Foundation Hospital, Urbana, Illinois, United States

and more 531 locations

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Phase 2

Completed

Conditions: EGFR-Mutated Non-Small-Cell Lung Carcinoma
Small Cell/Neuroendocrine

Interventions: Drug: Olaparib
Drug: Durvalumab

First Posted Date: 2020-09-04

Last Posted Date: 2024-12-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT04538378

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

Completed

Conditions: Ovary Cancer

Interventions: Drug: Olaparib

First Posted Date: 2020-08-31

Last Posted Date: 2024-10-31

Lead Sponsor: AstraZeneca

Target Recruit Count: 342

Registration Number: NCT04532645

Locations: 🇬🇧
Research Site, Swansea, United Kingdom

Olaparib in Patients With HRD Malignant Mesothelioma

Phase 2

Recruiting

Conditions: Mesothelioma
Homologous Recombination Deficiency

Interventions: Drug: Olaparib

First Posted Date: 2020-08-17

Last Posted Date: 2024-10-23

Lead Sponsor: University of Chicago

Target Recruit Count: 56

Registration Number: NCT04515836

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Pembrolizumab and Olaparib in Cervical Cancer Patients

Phase 2

Active, not recruiting

Conditions: Cervical Cancer
Cervical Carcinoma

Interventions: Drug: pembrolizumab
Drug: olaparib

First Posted Date: 2020-07-23

Last Posted Date: 2024-04-05

Lead Sponsor: John Diaz

Target Recruit Count: 8

Registration Number: NCT04483544

Locations: 🇺🇸
Miami Cancer Institute at Plantation, Plantation, Florida, United States
🇺🇸
Miami Cancer Institute, Miami, Florida, United States

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

Phase 3

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Olaparib
Drug: 5-FU
Drug: Bevacizumab
Drug: Capecitabine
Drug: Leucovorin/ levoleucovorin

First Posted Date: 2020-07-02

Last Posted Date: 2024-10-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 335

Registration Number: NCT04456699

Locations: 🇪🇸
Hospital Universitario Central de Asturias ( Site 1153), Oviedo, Asturias, Spain
🇺🇸
Providence Portland Medical Center ( Site 1400), Portland, Oregon, United States
🇺🇸
Oregon Health & Science University ( Site 1411), Portland, Oregon, United States

and more 126 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy